Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Influence of Caffeine Supplementation on Specific Performance and Training Activities

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03822663
Recruitment Status : Recruiting
First Posted : January 30, 2019
Last Update Posted : February 1, 2019
Sponsor:
Collaborator:
Poznan University of Physical Education
Information provided by (Responsible Party):
Krzysztof Durkalec-Michalski, PhD, Poznan University of Life Sciences

Brief Summary:
The purpose of this study is to verify the effect of acute caffeine (CAF) and placebo (PLA) supplementation on physical capacity and discipline-specific exercise performance in athletes, in a randomised, double-blind, placebo-controlled crossover trial.

Condition or disease Intervention/treatment Phase
Supplementation Sports Dietary Supplement: Caffeine supplementation Dietary Supplement: Placebo treatment Phase 3

Detailed Description:

Caffeine (CAF) is often proposed as an ergogenic agent, especially during high-intensity efforts. CAF supplementation may reduce effort-induced multi-faceted symptoms of fatigue and can improve psychomotor functions (like agility or decision-making processes), which is required during the intermittent high-intensity efforts in combat sports and speed-strength disciplines. Moreover, it is suggested that CAF treatment is associated with increased glycolytic activity during simulated or real training/competition bouts, which results in performance and physical capacity improvement.

However, there are hardly any data on the individual CAF-induced and dose-dependent changes in physical capacity and discipline-specific performance in combat sports and speed-strength disciplines. Therefore, the study aims to examine the effect of acute, different-dose CAF ingestion on physical capacity and discipline-specific performance in combat sports and speed-strength athletes, in a randomized, double-blind, placebo-controlled crossover trial.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Influence of Caffeine Supplementation on Discipline-Specific Performance and Training Activities in Combat Sports and Speed-Strength Disciplines
Actual Study Start Date : May 15, 2017
Estimated Primary Completion Date : February 1, 2020
Estimated Study Completion Date : March 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Caffeine supplementation
Group taking oral CAF (Caffeine) supplementation in a different-dose crossover regimen.
Dietary Supplement: Caffeine supplementation
The experimental procedure for each athlete includes an acute CAF supplementation in a different-dose crossover regimen in order to assess whether the dose affects the actual physical capacity and discipline-specific exercise performance (doses: 3.0-, 6.0- and 9.0 mg/kg of body mass, respectively). CAF (pure pharmaceutical caffeine) will be administered in the dissolved form. On testing days, the supplements will be taken 45 min before physical and exercise capacity test session. Between the CAF and PLA or a PLA and CAF treatments, a minimum 7-day washout period will be introduced.

Placebo Comparator: Placebo treatment
Group taking oral supplementation with placebo.
Dietary Supplement: Placebo treatment
The experimental procedure for each athlete will include PLA supplementation. Placebo will be administered in the dissolved form. On testing days, the PLA will be taken 45 min before physical and exercise capacity test session. Between the PLA and CAF or a CAF and PLA treatments, a minimum 7-day washout period will be introduced.




Primary Outcome Measures :
  1. Changes in discipline-specific exercise capacity after caffeine supplementation and placebo treatment [ Time Frame: Baseline and during 1 day of acute CAF and PLA supplementation ]
    Assessment of the discipline-specific exercise capacity tests carried out at baseline, and after CAF and PLA supplementation


Secondary Outcome Measures :
  1. Changes in sports training / competition activities after discipline-specific exercise tests [ Time Frame: Baseline and during 1 day of acute CAF and PLA supplementation ]
    Assessment of the sports training / competition activities after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation

  2. Changes in rate of perceived exertion after discipline-specific exercise tests [ Time Frame: Baseline and during 1 day of acute CAF and PLA supplementation ]
    Assessment of the Borg Rating of Perceived Exertion (RPE) scale after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation

  3. Changes in heart rate during discipline-specific exercise tests [ Time Frame: Baseline and during 1 day of acute CAF and PLA supplementation ]
    Assessment of the Heart Rate during and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • written consent to participate,
  • a current medical clearance to practice sports,
  • training experience: at least 2 years,
  • minimum of 4 workout sessions (in the discipline covered by the study) a week.

Exclusion Criteria:

  • current injury,
  • any health-related contraindication,
  • declared general feeling of being unwell,
  • unwilling to follow the study protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03822663


Contacts
Layout table for location contacts
Contact: Krzysztof Durkalec-Michalski, PhD +48 618 487 338 durkmich@up.poznan.pl
Contact: Paulina Nowaczyk, PhD +48 618 487 335 paulina.nowaczyk@up.poznan.pl

Locations
Layout table for location information
Poland
Poznan University of Life Sciences, ul.Wojska Polskiego 31 Recruiting
Poznań, Wielkopolska, Poland, 60-624
Contact: Krzysztof Durkalec-Michalski, PhD    +48 618 487 338    durkmich@up.poznan.pl   
Contact: Paulina Nowczyk, PhD    +48 618 487 338    paulina.nowaczyk@up.poznan.pl   
Sponsors and Collaborators
Poznan University of Life Sciences
Poznan University of Physical Education
Investigators
Layout table for investigator information
Principal Investigator: Krzysztof Durkalec-Michalski, PhD Poznan University of Life Sciences

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Krzysztof Durkalec-Michalski, PhD, Principal Investigator, Poznan University of Life Sciences
ClinicalTrials.gov Identifier: NCT03822663     History of Changes
Other Study ID Numbers: ULS00007
First Posted: January 30, 2019    Key Record Dates
Last Update Posted: February 1, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Shared data will be exclusively related to the level of recorded indicators, without personal data. The data obtained will be attached to scientific publications, depending on the requirements of the journal.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Krzysztof Durkalec-Michalski, PhD, Poznan University of Life Sciences:
Sports nutrition
Caffeine
Physical capacity
Exercise performance
Additional relevant MeSH terms:
Layout table for MeSH terms
Caffeine
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents